These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15741257)

  • 1. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life.
    Biermasz NR; Pereira AM; Smit JW; Romijn JA; Roelfsema F
    J Clin Endocrinol Metab; 2005 May; 90(5):2731-9. PubMed ID: 15741257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess.
    Biermasz NR; van Thiel SW; Pereira AM; Hoftijzer HC; van Hemert AM; Smit JW; Romijn JA; Roelfsema F
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5369-76. PubMed ID: 15531483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients.
    Wassenaar MJ; Biermasz NR; Kloppenburg M; van der Klaauw AA; Tiemensma J; Smit JW; Pereira AM; Roelfsema F; Kroon HM; Romijn JA
    Growth Horm IGF Res; 2010 Jun; 20(3):226-33. PubMed ID: 20194043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in treated patients with acromegaly.
    Kauppinen-Mäkelin R; Sane T; Sintonen H; Markkanen H; Välimäki MJ; Löyttyniemi E; Niskanen L; Reunanen A; Stenman UH
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3891-6. PubMed ID: 16849407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term biochemical status and disease-related morbidity in 53 postoperative patients with acromegaly.
    Serri O; Beauregard C; Hardy J
    J Clin Endocrinol Metab; 2004 Feb; 89(2):658-61. PubMed ID: 14764777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging trends in the diagnosis and treatment of acromegaly in Canada.
    Vallette S; Ezzat S; Chik C; Ur E; Imran SA; Van Uum S; Rivera J; Caspar-Bell G; Serri O
    Clin Endocrinol (Oxf); 2013 Jul; 79(1):79-85. PubMed ID: 23190441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up results of postoperative radiotherapy in 36 patients with acromegaly.
    Biermasz NR; van Dulken H; Roelfsema F
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2476-82. PubMed ID: 10902796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy.
    Peacey SR; Toogood AA; Veldhuis JD; Thorner MO; Shalet SM
    J Clin Endocrinol Metab; 2001 Jan; 86(1):259-66. PubMed ID: 11232010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly.
    Biermasz NR; van Dulken H; Roelfsema F
    J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of acromegalic arthropathy despite long-term biochemical control: a prospective, radiological study.
    Claessen KM; Ramautar SR; Pereira AM; Smit JW; Roelfsema F; Romijn JA; Kroon HM; Kloppenburg M; Biermasz NR
    Eur J Endocrinol; 2012 Aug; 167(2):235-44. PubMed ID: 22645199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly.
    van der Klaauw AA; Biermasz NR; Hoftijzer HC; Pereira AM; Romijn JA
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):123-8. PubMed ID: 18182092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlations of clinical parameters with quality of life in patients with acromegaly: Taiwan Acromegaly Registry.
    Tseng FY; Chen ST; Chen JF; Huang TS; Lin JD; Wang PW; Huey-Herng Sheu W; Chang TC;
    J Formos Med Assoc; 2019 Nov; 118(11):1488-1493. PubMed ID: 31147197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GH replacement improves quality of life and metabolic parameters in cured acromegalic patients with growth hormone deficiency.
    Giavoli C; Profka E; Verrua E; Ronchi CL; Ferrante E; Bergamaschi S; Sala E; Malchiodi E; Lania AG; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
    J Clin Endocrinol Metab; 2012 Nov; 97(11):3983-8. PubMed ID: 22904173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical-biochemical correlations in acromegaly at diagnosis and the real prevalence of biochemically discordant disease.
    Mercado M; Espinosa de los Monteros AL; Sosa E; Cheng S; Mendoza V; Hernández I; Sandoval C; Guinto G; Molina M
    Horm Res; 2004; 62(6):293-9. PubMed ID: 15542931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent negative illness perceptions despite long-term biochemical control of acromegaly: novel application of the drawing test.
    Tiemensma J; Pereira AM; Romijn JA; Broadbent E; Biermasz NR; Kaptein AA
    Eur J Endocrinol; 2015 May; 172(5):583-93. PubMed ID: 25724922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.